Stoke Therapeutics Inc. (STOK)
7.68
-0.17 (-2.17%)
At close: Mar 03, 2025, 12:24 PM
Stoke Therapeutics Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
| Revenue | 8.78M | 12.4M | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | n/a | 3.54M | 2.23M | 1.93M | 450K | 214K | 113K |
| Gross Profit | 8.78M | 8.87M | -2.23M | -1.93M | -450K | -214K | -113K |
| Operating Income | -114.77M | -104.36M | -86.06M | -53.04M | -35.68M | -12.78M | -5.55M |
| Interest Income | n/a | 3.12M | 120K | 744K | 3.35M | 270K | n/a |
| Pretax Income | -104.7M | -101.07M | -85.81M | -52.24M | -32.33M | -12.52M | -5.56M |
| Net Income | -104.7M | -93.11M | -84.71M | -50.61M | -28.52M | -12.52M | -5.56M |
| Selling & General & Admin | 41.32M | 38.92M | 31.9M | 20.85M | 11.91M | 4.41M | 1.96M |
| Research & Development | 82.23M | 77.84M | 54.17M | 32.2M | 23.76M | 8.37M | 3.6M |
| Other Expenses | n/a | 167K | 140K | 57K | 2K | -10K | -4K |
| Operating Expenses | 123.55M | 116.76M | 86.06M | 53.04M | 35.68M | 12.78M | 5.55M |
| Interest Expense | n/a | 3.12M | 120K | n/a | n/a | n/a | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 123.55M | 116.76M | 86.06M | 53.04M | 35.68M | 12.78M | 5.55M |
| Income Tax | n/a | -7.96M | -1.09M | -1.63M | -3.8M | 260K | n/a |
| Shares Outstanding (Basic) | 43.99M | 38.9M | 36.74M | 33.49M | 17.97M | 23.51M | 12.79M |
| Shares Outstanding (Diluted) | 43.99M | 38.9M | 36.74M | 33.49M | 17.97M | 23.51M | 12.79M |
| EPS (Basic) | -2.38 | -2.39 | -2.31 | -1.51 | -1.59 | -0.53 | -0.43 |
| EPS (Diluted) | -2.38 | -2.39 | -2.31 | -1.51 | -1.59 | -0.53 | -0.43 |
| EBITDA | -112.3M | -102.81M | -83.58M | -50.32M | -35.23M | -12.57M | -5.44M |
| Depreciation & Amortization | 2.47M | 3.54M | 2.23M | 1.93M | 450K | 214K | 113K |